首页> 外文期刊>Annals of Surgery >Small Hepatocellular Carcinoma With Low Tumor Marker Expression Benefits More From Anatomical Resection Than Tumors With Aggressive Biology
【24h】

Small Hepatocellular Carcinoma With Low Tumor Marker Expression Benefits More From Anatomical Resection Than Tumors With Aggressive Biology

机译:小肝细胞癌具有低肿瘤标志物的表达,从解剖学切除比具有侵略性生物学的肿瘤更多地受益于肿瘤

获取原文
获取原文并翻译 | 示例
       

摘要

Supplemental Digital Content is available in the text Objective: We assessed prognostic advantage of anatomical resection (AR) over nonanatomical resection (NAR) for hepatocellular carcinoma (HCC) according to multiplication of α-fetoprotein, des-γ-carboxyprothrombin, and tumor volume (ADV) scores. Background: Superiority of AR over NAR is debated. ADV score is surrogate marker of postresection prognosis for solitary HCC. Methods: This study included 1572 patients who underwent curative resection for solitary HCC of 2.0 to 5.0?cm between 2006 and 2014. Results: Preoperative patient profiles were not statistically different between AR and NAR groups. In 1324 na?ve patients without preoperative treatment, AR group showed lower recurrence rates ( P = 0.003) and higher patient survival rates ( P = 0.012) than NAR group. AR group showed lower recurrence rates in patients with ADV ≤5 log ( P ?≤?0.046). ADV scores >4 log and >3 log were independent risk factors for tumor recurrence and patient survival in treatment-na?ve patients, respectively. In treatment-na?ve group with preserved hepatic functional reserve, AR group showed lower recurrence rates in patients with ADV ≤4 log ( P = 0.026). Absence of microvascular invasion also showed lower recurrence rates ( P = 0.007) in AR group. In 248 patients with preoperative treatment, AR group showed lower recurrence rates ( P = 0.001) and higher patient survival rates ( P = 0.006). AR group showed lower recurrence rates in patients with ADV ≤4 log ( P < 0.001) and higher survival rates in patients with ADV ≤5 log ( P ?≤?0.043). Conclusions: Prognostic benefit of AR was evident in patients with ADV score ≤4 log or absence of microvascular invasion. Patients with less aggressive tumor biology benefit more from AR than NAR, thus being reasonably indicated for AR.
机译:文本目的中提供了补充数字内容:根据α-胎儿蛋白,DES-γ-羧基丙蛋白和肿瘤体积的倍增,我们评估了对肝细胞癌(HCC)的非致原癌(NAR)对非致抗体切除(NAR)的预后优点adv)得分。背景:NAR上AR的优越性是争论。 Adv得分是孤独HCC的替代性能预后的替代标记。方法:本研究包括1572名患者在2006年至2014年间孤立HCC治疗切除2.0至5.0厘米的患者。结果:术前患者谱系在AR和NAR组之间没有统计学不同。在1324岁的患者中没有术前治疗,AR组显示出较低的复发率(P = 0.003),比NAR组更高的患者存活率(P = 0.012)。 AR组患者患者的复发率较低(P?≤≤0.046)。 adv得分> 4 log和> 3日志分别是治疗 - naα患者肿瘤复发和患者存活的独立风险因素。在肝功能储备保存的肝功能储备的治疗中,AR组患者患者患者患者的较低复发率(P = 0.026)。在AR组中缺乏微血管侵袭也显示出较低的复发率(p = 0.007)。在248名术前治疗患者中,AR组显示出较低的复发率(P = 0.001)和更高的患者存活率(P = 0.006)。 AR组患者患者患者较低的复发率(P <0.001),患者患者的较高存活率(P?≤≤0.043)。结论:A1AD得分≤4患者的患者患者是显而易见的ar的预后益处,或者没有微血管侵袭。患者患有较低的肿瘤生物学的患者与NAR有益于AR,因此合理地表明AR。

著录项

  • 来源
    《Annals of Surgery》 |2019年第3期|共9页
  • 作者单位

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

    Department of Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 外科学;
  • 关键词

    hepatocellular carcinoma; microvascular invasion; recurrence; resection; tumor biology;

    机译:肝细胞癌;微血管侵袭;复发;切除;肿瘤生物学;
  • 入库时间 2022-08-20 01:21:15

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号